Abstract. Circulating tumor cells (CTCs) that detach from the primary tumor and move into the circulation are detected in patients with metastatic cancer. The discovery of such cancer cells has been used as a predictor of recurrence and prognosis, although a consensus regarding such applications has not been reached. Peritoneal cytology may be used for identifying high risk of recurrence or mortality, whereas the intraoperative presence of tumor cells in drainage veins, bone marrow, or the liver is not always useful for evaluating the prognosis. The reported positive rate for tumor cells in the peripheral blood of patients with colorectal cancer, including metastasis, has varied from 10 to 80%; however, numerous studies have demonstrated significant differences in the recurrence and mortality rates between patients with and without isolated tumor cells (ITCs) in the peripheral blood. However, the clinical significance of CTCs as an absolute prognostic factor has not been elucidated, since the measurement methodologies and/or the number of cases differed between the studies. Future prospective studies including larger patient populations may elucidate the utility of routine detection of ITCs in daily practice.
Introduction
Biomarkers predictive of the prognosis of colorectal cancer have been investigated using various materials and methods. With advances in immunohistochemistry (IHC) and molecular biology, occult tumor cells, including micrometastases in lymph nodes and circulating tumor cells (CTCs) in the peripheral blood, have been detected in patients with gastrointestinal and breast cancers (1) (2) (3) (4) (5) . By applying highly sensitive and specific diagnostic techniques, several prospective studies suggested that the presence of isolated tumor cells (ITCs) in peripheral areas, drainage veins and the bone marrow is associated with poor outcomes in colorectal cancer patients (6) (7) (8) (9) . ITCs are single tumor cells or small clusters of cells, ≤0.2 mm in greatest dimension, detectable by routine hematoxylin and eosin staining or IHC. Several reviews and meta-analyses evaluated clinical studies on ITCs in lymph nodes, peripheral blood, bone marrow and liver and suggested the prognostic significance of such cells in colorectal cancer patients (10) (11) (12) (13) (14) (15) .
To elucidate the findings of previous clinical studies assessing the prognostic value of disseminated tumor cells (DTCs) in patients with colorectal cancer, we investigated English literature over the past 10 years, using computer searches of PubMed with the following key words: 'colorectal cancer', 'micrometastasis', 'occult metastasis', 'circulating tumor cell', 'disseminated tumor cell', 'isolated tumor cell', 'lymph node', 'peritoneal cavity', 'peripheral blood', 'drainage vein', 'bone marrow', 'liver', 'prognosis', and 'survival'. After reading all the abstracts and reviewing the available studies, a total of 87 studies were collected and included in this review.
Tumor cells in lymph nodes
Between January, 2002 and March, 2012, a total of 31 studies assessed the prognostic value of tumor cells in histologically negative lymph nodes of patients with colorectal cancer (Table I) . The studies investigated a total of 4,080 patients with colorectal (n=20), colon (n=7) and rectal (n=4) cancer, with a median cohort size of 105 patients. The majority of the studies detected tumor cells using a marker of cytokeratin (CK) and IHC techniques.
Positive rates for tumor cells in histologically negative lymph nodes varied considerably among these studies, ranging from 5 to 88% (median, 30%). With median followup periods of 24-128 months (median, 60 months), 16 out of 
Tumor cells in the peritoneal cavity
During the same period, 13 studies assessed the prognostic value of tumor cells in the peritoneal cavity of patients with colorectal cancer (Table II) (34, (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) . The studies investigated a total of 2,434 colorectal cancer patients (median, 125 patients). The majority of these studies used standard cytological methods to detect tumor cells in peritoneal lavage samples.
Positive rates for tumor cells in the peritoneal cavity varied among studies, ranging from 2 to 33% (median, 17%). The median follow-up period was 47 months (range, 25-103 months) and 9 out of the 13 studies (69%) demonstrated significant differences in recurrence and/or mortality rates between patients with and without ITCs in the peritoneal cavity.
Tumor cells in the peripheral blood
A total of 22 studies assessed the prognostic value of tumor cells in the peripheral blood of patients with colorectal cancer (Table III) Positive rates for tumor cells in the peripheral blood ranged from 10 to 62% (median, 38%). Following the exclusion of 9 studies on stage IV patients, the positive rate for tumor cells among the studies was 22-62% (median, 36%). With a median follow-up period of 40 months (range, 24 to >70 months), 15 out of the 22 studies (68%) demonstrated significant differences in recurrence and/or mortality rates between patients with and without ITCs in the peripheral blood. Among the 14 studies including only stage I/II/III patients, 12 (86%) demonstrated a prognostic value of ITCs.
Tumor cells in drainage veins
Six studies assessed the prognostic value of tumor cells in drainage veins sampled from the mesenteric or portal vein during surgery (Table IV) (63, 65, (80) (81) (82) (83) . The studies investigated patients with colorectal cancer, including a total of 638 patients (median, 94 patients). Tumor cells were detected using a CEA marker and RT-PCR.
The positive rate for tumor cells in the drainage vein varied from 11 to 49% (median, 43%). With a median follow-up period of 46 months (range, 30 to ≥60 months), 4 out of the 6 studies (67%) demonstrated a significant difference in recurrence and/or mortality rates between patients with and without ITCs in the drainage veins. transcriptase-polymerase chain reaction; IHC, immunohistochemistry; CSS, CellSearch system; R, recurrence rate; M, mortality rate; NA, not available; HR, hazard ratio.
Tumor cells in the bone marrow
Four studies assessed the prognostic value of tumor cells in the bone marrow (Table V) (34, 66, 84, 85) . The studies included a total of 514 colorectal cancer patients (median, 115 patients). These studies detected tumor cells using a CK marker and immunocytochemistry (ICC) or RT-PCR techniques. Positive rates of tumor cells in the bone marrow varied from 17 to 64% (median, 29%). With a median follow-up of 60 months (range, 55-112 months), only 1 in 4 studies (25%) demonstrated a significant difference in recurrence and/or mortality rates between patients with and without ITCs in the bone marrow.
Isolated tumor cells in stage IV patients
We identified 9 studies assessing the prognostic value of tumor cells in the peripheral blood of patients with metastatic colorectal cancer (Table VI) (86) (87) (88) (89) (90) (91) (92) (93) (94) . The positive rate of tumor cells in the peripheral blood varied from 15 to 80% (median, 30%). Median follow-up was 25 months (range, 11 to ≥38 months) and 7 studies (78%) demonstrated a significant difference in recurrence and/or mortality rates between patients with and without ITCs in the peripheral blood.
Seven studies assessed the prognostic value of tumor cells in the bone marrow of patients with liver metastasis (Table VII) (86, 88, (95) (96) (97) (98) (99) . The median positive rate for tumor cells in peripheral blood was 22% (range, 7-50%). The median follow-up period was 35 months (range, 18 to ≥43 months) and 4 studies (57%) demonstrated a significant difference in recurrence and/or mortality rates between patients with and without ITCs in the bone marrow.
Five studies assessed the prognostic value of tumor cells in the normal liver tissue of patients with liver metastasis, excluding 1 study comprising only stage I/II/III patients (Table VIII) (89, (100) (101) (102) (103) . The positive rate for tumor cells in the peripheral blood varied considerably among the studies (10-70%; median, 37%). With a median follow-up period of 44 months (range, 1 to ≥5 months), 3 studies (60%) demonstrated significant differences in recurrence and/or mortality rates between patients with and without ITCs in the normal liver tissue.
Conclusion
Although IHC and molecular techniques are useful for detecting tumor cells in histologically negative lymph nodes, the prognostic significance of such cells is equivocal among recent 10-year studies (104) . Peritoneal cytology during curative resection ocasionally detects tumor cells and may be useful in identifying a high risk of recurrence or mortality, whereas the presence of tumor cells during surgery in the drainage vein, bone marrow, or liver is not always useful for evaluating the prognosis (105) .
Recent studies demonstrated that identifying ITCs in the peripheral blood is useful for estimating the outcome of patients with localized as well as metastatic cancer (106, 107) . ITCs in the peripheral blood may be measured using the CellSearch system (4,5,108-112) and future prospective studies based on large patient samples and long-term follow-up may elucidate Table ⅥⅠⅠ 
